FDA Brief

Warning letters Devices

FDA warning letter to

Skytron, LLC

High riskIssued May 19Posted Jul 7Center for Devices and Radiological Health

Skytron marketed four UV disinfection devices without FDA clearance or approval and kept unapproved medical claims after promising to remove them.

What happened

FDA reviewed Skytron's website on May 11, 2026, plus two brochures, and found the 1140 Sentry, 2280 Syndicate, 3200 Max and UV Smart D25 promoted to disinfect hospital rooms and medical equipment such as IV pumps, stethoscopes and thermometers. FDA says the firm has no approved premarket application (PMA, a full FDA review and approval) and no cleared 510(k) (a shorter premarket review) for these devices, and that its brochure calls the UV Smart D25 "FDA registered" in a way that suggests FDA approval. FDA had written to the firm about these claims since February 2022, and the firm said in July 2024 it had removed healthcare-use claims from its website.

What FDA found

  1. The four devices are marketed without an approved premarket application or an investigational device exemption, which makes them adulterated.

    Section 501(f)(1)(B), 21 U.S.C. § 351(f)(1)(B)
  2. The firm did not submit a 510(k) premarket notification before putting the devices into commercial distribution, which makes them misbranded.

    Section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k); 21 CFR 807.81
  3. The UV Smart D25 brochure cites the firm's FDA registration while describing cleaning of medical equipment, which misleadingly suggests FDA approval or endorsement.

    Section 502(a), 21 U.S.C. § 352(a); 21 CFR 807.39
  4. The UV Smart D25 does not qualify for the 510(k) exemption for medical washer-disinfectors because it has no mechanical cleaning step and uses UV-C light rather than thermal or chemical disinfection.

    21 CFR 880.6992
  5. The firm gave FDA no evidence supporting claims that its devices reduce germs by log-4 or 5-log levels or disinfect hospital rooms and equipment.

  6. The website and brochures still carry healthcare-use claims after the firm told FDA in July 2024 that it had removed them.

What FDA wants

FDA tells the firm to stop any activity that misbrands or adulterates the four devices, including selling them for the uses described, and to report in writing the corrections and corrective actions taken and how it will prevent repeat violations.

Who should pay attention

  • hospital infection prevention and sterile processing teams evaluating UV disinfection devices
  • distributors and group purchasing organizations that resell these devices
  • device makers who cite FDA registration in marketing materials

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. ZIIP, Inc.

    FDA warns ZIIP over quality-system violations and unapproved marketing of HALO 2.0, DOT, and gels.

    High risk
  2. Longhorn Vaccines and Diagnostics LLC

    Longhorn Vaccines and Diagnostics sold its PrimeStore MTM sample transport device without required quality controls or clearance for claims beyond its approved uses.

    High risk